Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2021 2
2022 1
2024 1
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Among authors: van bekkum ml. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. Among authors: van bekkum ml. Lancet Oncol. 2025 Oct;26(10):1346-1356. doi: 10.1016/S1470-2045(25)00363-8. Epub 2025 Sep 10. Lancet Oncol. 2025. PMID: 40945523 Clinical Trial.
Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01).
de Groot AF, Cohen D, Heijns JB, Mandigers CMPW, van de Wouw AJ, Cloos-van Balen M, Ropela JA, Oosterkamp HM, van Bekkum ML, Houtsma D, Putter H, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Dijkstra KL, van Leeuwen-Stok AE, van der Burg SH, Liefers GJ, Linn SC, Kroep JR. de Groot AF, et al. Among authors: van bekkum ml. Clin Cancer Res. 2025 Aug 1;31(15):3175-3181. doi: 10.1158/1078-0432.CCR-24-3402. Clin Cancer Res. 2025. PMID: 40495424 Clinical Trial.
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.
Guchelaar NAD, Mathijssen RHJ, de Boer M, van Bekkum ML, Heijns JB, Vriens BEPJ, van Rosmalen MM, Kessels LW, Hamming L, Beelen KJ, Nieboer P, van den Berg SM, Hoop EO, Bijlsma RM, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Guchelaar NAD, et al. Among authors: van bekkum ml. EClinicalMedicine. 2025 Jan 27;80:103065. doi: 10.1016/j.eclinm.2024.103065. eCollection 2025 Feb. EClinicalMedicine. 2025. PMID: 40017682 Free PMC article.
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Bouwer NI, Steenbruggen TG, Rier HN, Kitzen JJEM, Smorenburg CH, van Bekkum ML, de Jong PC, Drooger JC, Holterhues C, Kofflard MJM, Boersma E, Sonke GS, Levin MD, Jager A. Bouwer NI, et al. Among authors: van bekkum ml. Int J Cancer. 2022 Aug 15;151(4):616-622. doi: 10.1002/ijc.34024. Epub 2022 Apr 27. Int J Cancer. 2022. PMID: 35403708 Free PMC article.
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Bouwer NI, Steenbruggen TG, van Rosmalen J, Rier HN, Kitzen JJEM, van Bekkum ML, Tije AJT, de Jong PC, Drooger JC, Holterhues C, Smorenburg CH, Kofflard MJM, Boersma E, Sonke GS, Levin MD, Jager A. Bouwer NI, et al. Among authors: van bekkum ml. Breast Cancer Res Treat. 2021 Apr;186(3):851-862. doi: 10.1007/s10549-020-06039-w. Epub 2021 Jan 4. Breast Cancer Res Treat. 2021. PMID: 33394273 Free PMC article.
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial.
Dekker EN, Theijse RT, van Dam JL, Janssen QP, Stoop TF, Bonsing BA, Bosscha KP, Bouwense SAW, Busch OR, Coene PLO, van Eijck CHJ, van Her Harst E, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Mieog JSD, Nieuwenhuijs VB, Patijn GA, van Santvoort HC, Schreinemakers JMJ, de Wilde RF, Wit F, Zonderhuis BM, Homs MYV, van Tienhoven G, Wilmink JW, Besselink MG, Koerkamp BG; Dutch Pancreatic Cancer Group. Dekker EN, et al. Ann Surg. 2025 Aug 12. doi: 10.1097/SLA.0000000000006910. Online ahead of print. Ann Surg. 2025. PMID: 40792645
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
van der Sijde F, Homs MYV, van Bekkum ML, van den Bosch TPP, Bosscha K, Besselink MG, Bonsing BA, de Groot JWB, Karsten TM, Groot Koerkamp B, Haberkorn BCM, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, Wilmink JW, van Eijck CHJ, Vietsch EE, On Behalf Of The Dutch Pancreatic Cancer Group. van der Sijde F, et al. Among authors: van bekkum ml. Int J Mol Sci. 2021 Oct 9;22(20):10902. doi: 10.3390/ijms222010902. Int J Mol Sci. 2021. PMID: 34681562 Free PMC article.
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM. Wortelboer N, et al. Among authors: van bekkum ml. Eur J Cancer. 2025 Dec 9;231:116051. doi: 10.1016/j.ejca.2025.116051. Epub 2025 Oct 25. Eur J Cancer. 2025. PMID: 41207182 Free article. Clinical Trial.
11 results